Diabetes remains one of the most widespread chronic diseases, affecting over 537 million adults globally. While traditional treatments such as insulin therapy and dietary modifications help manage the condition, they do not address the underlying causes of the disease. GATC Health Corp., a biotechnology company integrating artificial intelligence (AI) into drug discovery, has been exploring an alternative approach that leverages a patient’s own stem cells to improve blood sugar regulation and potentially reduce long-term complications.
A review article published in the American Journal of Biomedical Science & Research details GATC Health’s research into autologous bone marrow-derived mononuclear cell (BMMNC) infusion. This approach involves extracting stem cells from a patient’s bone marrow, processing them, and reintroducing them into the body to restore insulin-producing cell function. The goal is to offer a more personalized therapy that minimizes the risk of immune rejection, a challenge commonly associated with other cell-based treatments.
The review highlights findings from early clinical trials, which indicate that autologous stem cell therapy may provide several benefits for individuals with diabetes:
- Improved Blood Sugar Control: Patients in initial studies showed significant improvements in glycemic regulation and insulin production.
- Reduced Medication Dependence: Some patients required lower doses of insulin and other diabetes medications following treatment.
- Long-Lasting Effects: Benefits of the therapy were observed for up to 36 months post-infusion in certain cases.
- Application Beyond Diabetes: It also suggests potential applications for neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
The research also integrates GATC Health’s AI-based Multiomics Advanced Technology™ (MAT) platform, which assists in patient selection and post-treatment monitoring. By analyzing multi-omics data, MAT helps identify the most suitable candidates for stem cell therapy and tracks their response over time.
Dr. Jonathan RT Lakey, PhD, MSM, Professor Emeritus at UC Irvine and Chair of GATC Health’s Scientific Advisory Board, noted,
“This innovative therapy represents a significant leap forward in diabetes treatment. By harnessing the regenerative power of a patient’s own stem cells, we’re opening new doors for long-term disease management and potentially improved quality of life for millions of diabetes sufferers.”
